AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.

AURKB activates MAD2L2 expression to downregulate the p53 DDR pathway, thereby promoting BC progression. Thus, AURKB may serve as a potential molecular marker and a novel anticancer therapeutic target for BC.